TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:
CGEN), a leading predictive drug discovery company, today announced
that aspects of its immuno-oncology programs and its lead autoimmune
program will be presented at four upcoming scientific conferences.
In poster presentations at three upcoming oncology conferences,
Compugen’s scientists will present the Company’s unique predictive
discovery approach for novel drug targets with an emphasis on selected
novel immune checkpoint programs which are now being advanced by the
Company in the field of cancer immunotherapy.
Arthur Machlenkin, Ph.D., Head of Immuno-Oncology Research at Compugen,
will present at the CRI-CIMT-EATI-AACR
- The Inaugural International Cancer Immunotherapy Conference:
Translating Science into Survival, to be held between September
16-19, 2015, in New York.
Ofer Levy, Ph.D., Principal Scientist at Compugen, will present at the 7th
International Conference on Tumor Microenvironment, to be held
between October 11-15, 2015, in Tel Aviv, Israel.
Galit Rotman, Ph.D., Chief Scientist, Therapeutics at Compugen, will
present at the Society
for Immunotherapy of Cancer’s (SITC’s) 30th Anniversary Annual Meeting &
Associated Programs, to be held between November 4-8, 2015, in
National Harbor, MD.
The Company’s lead program for autoimmune diseases, CGEN-15001, a
therapeutic fusion protein based on a Compugen-discovered immune
checkpoint protein candidate, will be the subject of an oral
presentation by Iris Hecht, Ph.D., Principal Scientist at Compugen, at
the American
College of Rheumatology Annual Meeting to take place between
November 6-11, 2015, in San Francisco. Dr. Hecht’s talk, on Sunday,
November 8, titled "CGEN-15001, a Novel B7-like Protein, Controls
Inflammation in a Translational Rheumatoid Arthritis (RA) Assay and
Induces Treg Driven Long-Term Remission in an Autoimmune Disease Model,"
will be given as part of the Cytokines, Mediators, Cell-cell Adhesion,
Cell Trafficking and Angiogenesis session and will include recent data
for CGEN-15001 obtained using immune cells of rheumatoid arthritis
patients.
About Compugen
Compugen is a leading drug discovery company utilizing its broadly
applicable predictive discovery infrastructure to identify novel drug
targets and develop first-in-class biologics. The Company’s current
pipeline focus is on immune checkpoint target candidates discovered by
the Company, potentially providing the basis for a next wave of
therapeutics for cancer immunotherapy. Compugen’s business model is
based on selectively entering into collaborations for its novel targets
and drug product candidates at various stages of research and
development under revenue-sharing agreements. The Company is
headquartered in Tel Aviv, Israel, with R&D facilities in Tel Aviv and
South San Francisco. At the US facilities, monoclonal antibody
therapeutic candidates are discovered and developed against the
Company’s novel target candidates. For additional information, please
visit Compugen's corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of terminology
such as “will,” “may,” “expects,” “anticipates,” “believes,” and
“intends,” and describe opinions about future events. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of Compugen to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks include: that Compugen’s
business model is substantially dependent on entering into collaboration
agreements with third parties and may not be successful in generating
revenues, and that the development and commercialization of therapeutic
products includes many inherent risks, including failure to progress to
clinic or, if progressed, failure to receive regulatory approval. These
and other factors are more fully discussed in the "Risk Factors" section
of Compugen’s most recent Annual Report on Form 20-F as filed with the
Securities and Exchange Commission as well as other documents that may
be subsequently filed by Compugen from time to time with the Securities
and Exchange Commission. In addition, any forward-looking statements
represent Compugen’s views only as of the date of this release and
should not be relied upon as representing its views as of any subsequent
date. Compugen does not assume any obligation to update any
forward-looking statements unless required by law.